Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Background: Osimertinib is a 3rd-generation tyrosine kinase inhibitor (TKI) that blocks the epidermal growth factor receptor (EGFR) in non-small lung cancer (NSCLC) and has dramatically improved outcomes for patients with EGFR mutations. While gastrointestinal complications such as diarrhea have bee...

Full description

Bibliographic Details
Main Authors: Tejas Patil, Jose M. Pacheco, Anastasios Dimou, William T. Purcell, Candice Rossi, Paul A. Bunn, Robert C. Doebele, D. Ross Camidge, Lisa Ferrigno
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Oncology
Subjects:
EGFR
NSCLC
tyrosine kinase inhibitor
osimertinib
volvulus
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00510/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00510/full

Similar Items